Thermo Fisher Scientific Inc. $TMO Stock Holdings Lifted by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 155,228 shares of the medical research company’s stock after acquiring an additional 2,389 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Thermo Fisher Scientific were worth $76,299,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $170,000. Raymond James Financial Inc. boosted its position in Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its stake in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target for the company. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Finally, Robert W. Baird cut their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $606.45.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $573.43 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $213.10 billion, a PE ratio of 31.52, a PEG ratio of 2.33 and a beta of 0.87. The firm’s 50 day moving average price is $491.42 and its 200 day moving average price is $513.08. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, ahead of the $5.71 consensus, with revenue of $11.99 billion also topping estimates. Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today
• Positive Sentiment: Management raised full-year FY2026 guidance, with EPS and revenue outlooks both coming in above Wall Street expectations, signaling confidence in continued demand and execution. Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights
• Positive Sentiment: Improving customer activity across end markets and continued organic growth helped ease investor concerns about a prolonged slowdown in medical research and tools demand. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Separately, Thermo Fisher was selected by ImmuPharma to help manufacture its Kapiglucagon diabetes candidate, a modest business development update that supports the company’s CDMO pipeline but is not likely to move shares on its own. ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.